Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD


June 24, 2021

Figure 1. Glucagon-like peptide 1 (GLP1, 7-36) molecule. GLP-1 analogues are used in the treatment of diabetes.

Guidelines from the American Diabetes Association/European Association for the Study of Diabetes, the American Association of Clinical Endocrinology, and the International Diabetes Federation recommend that GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors be considered as an alternative to or in combination with metformin for patients who have not reached their glycemic target.

Other indications for incretin-based therapy include when metformin, a sulfonylurea, or pioglitazone is contraindicated or not tolerated, and/or when hypoglycemia and weight gain are special considerations.

Data has shown that incretin-based therapies can improve glycemic efficacy alone or in combination with other oral antidiabetic drugs, supporting incremental glycemia lowering with both DPP-4 inhibitors and GLP-1 receptor agonists regardless of background therapy.

Learn more about pharmacologic therapy in type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: